Division of Vascular and Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School , 1 Deaconess Road, Boston, MA, 02215, USA.
Division of Interventional Radiology, Oschner Clinic, New Orleans, LA, USA.
Cardiovasc Intervent Radiol. 2022 Oct;45(10):1540-1546. doi: 10.1007/s00270-022-03240-w. Epub 2022 Aug 17.
To describe the feasibility and outcomes of filter-assisted shunt embolization in patients with acquired large portosystemic shunts.
Two-center HIPAA compliant retrospective study of all patients who underwent filter-assisted shunt embolization between 03/2015-03/2021. Initial clinical evaluation, including demographic information, shunt sizing, and procedural details, was reviewed. Technical success was defined as successful occlusion of the targeted shunt.
Eight patients (55 ± 10 years/88% male) had a large acquired portosystemic shunt which was suitable for filter-assisted shunt embolization. Indications for the procedure: 3 = pre-transplantation optimization, 2 = overt hepatic encephalopathy (HE), 1 = post-transplant thrombosis, 1 = portal vein thrombosis and encephalopathy, 1 = encephalopathy and variceal bleeding. Portosystemic shunts occurred between splenic and renal veins, inferior mesenteric and gonadal veins, and coronary veins. Mean shunt diameter was 27 ± 5 mm. The technical success of the procedure was 8/8 (100%). In 7 patients, a transjugular intrahepatic portosystemic shunt (TIPS) was also placed at the time of the shunt embolization due to either pre-transplant indication or sluggish portal flow. There were no intraprocedural complications from filter placement.
3 = currently listed for transplant, 2 = resolution of HE, 1 = made CMO, 1 patient with patent post-transplant vasculature. 1 = died as a complication related to TIPS placement (SIR Class F Complication).
Filter-assisted shunt embolization is a technically feasible and safe technique to reduce or embolize large portosystemic shunts.
描述在患有获得性大脾肾分流的患者中使用滤网辅助分流栓塞的可行性和结果。
对 2015 年 3 月至 2021 年 3 月间在两个中心进行滤网辅助分流栓塞的所有患者进行 HIPAA 合规性回顾性研究。回顾了初始临床评估,包括人口统计学信息、分流管大小和程序细节。技术成功定义为目标分流管的成功闭塞。
8 名患者(55±10 岁/88%男性)存在适合滤网辅助分流栓塞的大获得性脾肾分流。该手术的适应证为:3 例=移植前优化,2 例=显性肝性脑病(HE),1 例=移植后血栓形成,1 例=门静脉血栓和脑病,1 例=脑病和静脉曲张出血。脾肾分流发生在脾静脉和肾静脉、肠系膜下静脉和性腺静脉、冠状静脉之间。平均分流管直径为 27±5mm。该手术的技术成功率为 8/8(100%)。在 7 例患者中,由于移植前的适应证或门静脉血流缓慢,在分流栓塞时同时放置了经颈静脉肝内门体分流术(TIPS)。滤网放置无术中并发症。
3 例=目前列入移植名单,2 例=HE 缓解,1 例=CMO,1 例移植后血管通畅。1 例=因 TIPS 放置相关并发症死亡(SIR 分级 F 并发症)。
滤网辅助分流栓塞是一种技术上可行且安全的技术,可减少或栓塞大的脾肾分流。